$NOVN Some thoughts to lead into next week: If we step back from trial results and look at the bigger picture, Novan’s pipeline seems to be converging into the (relative) near-term. -SB206 is nearing a presumptive phase 3 trial pass, on its way to commercialization. -COVID candidate is being floated for rapid testing and approval. -SB208 (anti-fungal) and SB204 (acne) are ready for phase 3, pending funding. It will take time for this to manifest, but the next 2-3 years could see more rapid growth than Novan’s entire history to date. No wonder they’ve been looking for new digs.